Literature DB >> 8834791

pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel.

R Williams1, G W Stamp, C Gilbert, M Pignatelli, E N Lalani.   

Abstract

We describe the first model system employing human pS2 gene transfer and expression in a non-pS2-expressing cell line, mouse mammary adenocarcinoma 410.4, in order to analyse the potential effect of human trefoil peptide pS2 in glandular epithelium. Two selected clones, AA4 and AD4, were established and shown to have incorporated the pS2 cDNA sequence into the genome, express pS2 containing transcript and produce the pS2 peptide. When grown in 3-D collagen gels both transfectants show striking morphological changes compared to the vector control clone (VA5). VA5 forms large cohesive spherical aggregates with rare coarse spicular outgrowths, accompanied by prominent hyalinised extracellular matrix deposition. pS2 transfectants form poorly cohesive, stellate colonies with very little or no matrix deposition, radiating long cords composed of single elongated cells, an effect previously observed in other cell lines with hepatocyte growth factor. pS2 transfection had no demonstrable effect on proliferation and this is not a morphogenetic phenomenon, as tubulogenesis is not seen. Motility assays suggest that the pS2 'dispersant' effect in collagen gels is due to an increase in cell motility. There were no measurable alterations in either E-cadherin expression or E-cadherin-dependent cell-cell aggregation. pS2 may play a role in maintenance and restitution of mucosal integrity by accelerating migration/dispersion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834791     DOI: 10.1242/jcs.109.1.63

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  9 in total

Review 1.  Trefoil peptides.

Authors:  W M Wong; R Poulsom; N A Wright
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 2.  Modulation of epithelial cell adhesion in gastrointestinal homeostasis.

Authors:  J A Efstathiou; M Pignatelli
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

3.  Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2.

Authors:  R S Rosenberg Zand; D J Jenkins; E P Diamandis
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

4.  Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat.

Authors:  S S Poulsen; J Thulesen; E Nexø; L Thim
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

5.  Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58.

Authors:  M P Chadwick; B R Westley; F E May
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

6.  Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat.

Authors:  S S Poulsen; J Thulesen; L Christensen; E Nexo; L Thim
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 7.  Aspects of the biology of regeneration and repair in the human gastrointestinal tract.

Authors:  N A Wright
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

8.  The intestinal trefoil factor (Tff3), also expressed in the inner ear, interacts with peptides contributing to apoptosis.

Authors:  M Lubka; A A Shah; N Blin; M Baus-Loncar
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

9.  The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions.

Authors:  Jörn Heuer; Franziska Heuer; René Stürmer; Sönke Harder; Hartmut Schlüter; Nayara Braga Emidio; Markus Muttenthaler; Dörthe Jechorek; Frank Meyer; Werner Hoffmann
Journal:  Int J Mol Sci       Date:  2020-04-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.